1 / 3

TIBSOVO SUPPLIER IN INDIA | 9310090915

TIBSOVO (ivosidenib) is a targeted therapy used in the treatment of acute myeloid leukemia (AML) in adults with specific mutations in the IDH1 gene. It's a type of enzyme inhibitor and works by blocking the action of the mutated IDH1 enzyme, which can reduce the growth and division of cancer cells.

shalukimm
Download Presentation

TIBSOVO SUPPLIER IN INDIA | 9310090915

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TIBSOVO SUPPLIER IN INDIA | 9310090915 Tibsovo: Indica.on and Usage Tibsovo is an FDA-approved isocitrate dehydrogenase-1 (IDH1) inhibitor used to treat adult pa>ents who have a suscep>ble IDH1 muta>on as detected by an FDA-approved test with: AML (Acute Myeloid Leukaemia) is a kind of blood cancer. AML pa>ents over the age of 75 who have comorbidi>es that prevent vigorous induc>on chemotherapy from being administered AML that has relapsed or is refractory Cholangiocarcinoma, either localized or metasta>c Pa>ents suffering from locally advanced or metasta>c cholangiocarcinoma who have previously been treated This effec>ve medica>on is available on the market and can be obtained from any reputable dealer. Furthermore, the Tibsovo price in India is >ny and incredibly reasonable, making it simple to incorporate it into therapy. Tibsovo: Dosage and Administra.on Tibsovo 250 mg Tablets are available. Tibsovo should be taken once a day orally un>l disease progression or severe toxicity occurs. Tibsovo can be administered with or without food. Tibsovo should not be used with a high- fat meal due to an increase in Tibsovo concentra>on [see Warnings and Precau>ons (5.2) and Clinical Pharmacology]. Tibsovo pills should not be crushed or divided. Tibsovo pills should be taken orally at the same >me every day. If a Tibsovo dose is vomited, do not replace it; rather, wait un>l the next scheduled dose is due. If a Tibsovo dose is missed or not taken on >me, it should be given as soon as possible and minimum 12 hours before the next scheduled dose. Return to your regular schedule the next day. Do not take two doses within 12 hours of each other. Tibsovo: Warnings and Precau.ons Electrocardiograms and electrolytes should be checked for QTc interval prolonga>on. If QTc interval prolonga>on occurs, reduce or pause the dose, then resume the dose or discon>nue Tibsovo permanently. Guillain-Barre Syndrome (GBS): Keep a look out for indica>ons and symptoms of new motor and/or sensory impairments in pa>ents. Quit Tibsovo for good if you have Guillain-Barré syndrome. This powerful pharmaceu>cal is on the market and may be obtained from any respectable vendor. Furthermore, the Tibsovo price in India is economical, making it simple to incorporate it into treatment. Tibsovo: Drug Interac.on Strong or moderate CYP3A4 inhibitors: Reduce TIBSOVO dosage when using strong CYP3A4 inhibitors. Pa>ents should be closely watched for signs of QTc interval prolonga>on. Inducers of CYP3A4: Avoid using TIBSOVO (7.1, 12.3) simultaneously. If you have sensi>ve CYP3A4 substrates, avoid using TIBSOVO (7.2, 12.3) at the same >me. Avoid taking QTc prolonging medica>ons with TIBSOVO. Healthcare professionals should monitor the pa>ents for an increased risk of QTc interval prolonga>on if coadministra>on is unavoidable.

  2. If someone develop signs and symptoms of differen>a>on syndrome, the healthcare provider may treat the pa>ent with a cor>costeroid medicine or a medicine called hydroxyurea and may monitor you in the hospital. You can easily buy Tibsovo tablets from India at a lower cost through Indian Pharma Network at a more reasonable and pocket-friendly price. We are the most dependable and trustworthy generic pharmaceu>cal suppliers in India. You can visit us at Tibsovo: Adverse Reac.ons Although the price of Tibsovo is reasonable, the following drug interac>ons must be understood before using the drug. Inquire with your doctor for further informa>on. The most common adverse symptoms (20%) in AML pa>ents were fa>gue, arthralgia, leukocytosis, diarrhea, edema, nausea, dyspnea, mucosi>s, and ECG. QT prolonga>on symptoms include rash, cough, decreased appe>te, myalgia, cons>pa>on, and pyrexia. The most common laboratory abnormali>es (20%) in AML pa>ents were hemoglobin decrease, calcium decrease, sodium decrease, magnesium decrease, uric acid decrease, potassium decrease, alkaline phosphatase decrease, aspartate aminotransferase decrease, phosphate decrease, and crea>nine decrease. The most common side effects (15%) in pa>ents with cholangiocarcinoma were fa>gue, nausea, stomach discomfort, diarrhea, cough, decreased appe>te, ascites, vomi>ng, anemia, and rash. The most common laboratory abnormali>es in cholangiocarcinoma pa>ents (10%) were reduced hemoglobin, increased aspartate aminotransferase, and high bilirubin. Tibsovo: Mechanism of Ac.on Ivosidenib is a small molecule inhibitor that prevents the mutant isocitrate dehydrogenase 1 (IDH1) enzyme from working. Suscep>ble IDH1 muta>ons in AML pa>ents are those that result in increased 2-hydroxyglutarate (2-HG) levels in leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of ivosidenib and/or 2) inhibi>on of mutant IDH1 enzyma>c ac>vity at ivosidenib concentra>ons sustainable at the recommended dosage using validated methods. The R132H and R132C altera>ons are the most common in AML pa>ents. Ivosidenib inhibited selected IDH1 R132 mutants in vitro at significantly lower dosages than wild-type IDH1. In mouse xenograh models of AML with an IDH1 muta>on, ivosidenib inhibited the mutant IDH1 enzyme, lowering 2HG levels and increasing myeloid growth in vitro and in vivo. In blood samples from pa>ents with AML with mutant IDH1, ivosidenib reduced ex-vivo 2-HG levels, blast counts, and the frac>on of mature myeloid cells. Tibsovo: Descrip.on about the drug The chemical formula is C28H22ClF3N6O3, and the molecular weight is 583.0 g/mol. In aqueous solu>ons with pH values ranging from 1.2 to 7.4, ivosidenib is largely insoluble. Tibsovo (ivosidenib) film-coated 250 mg tablets are available for oral use. Colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate are among the inac>ve ingredients in each tablet. The tablet coa>ng contains FD&C blue #2, hypromellose, lactose monohydrate, >tanium dioxide, and triace>n. The drug can be obtained from any generic and innova>ve provider who has license to do so under a valid and recognised prescrip>on and who follows the relevant regula>ons. Indian

  3. Pharma Network is one of the most trusted and dependable generic pharmaceu>cal suppliers, and you can buy Tibsovo online from us at extremely low prices. Source - hmps://helpforheallth.blogspot.com/2023/05/>bsovo-indica>on-and-usage.html

More Related